GloGen Clinical Research Pvt. Ltd. has received the Establishment Inspection Report (EIR) from USFDA, with the determination of “Closed”, auditorium conducted on 09th -13th February 2026.
The “Closed” designation means that the inspection is concluded with no objectionable findings — given the firm’s compliance to regulatory standards and robust quality management practices.
The company said the outcome underscores its ongoing emphasis on regulatory excellence and operational integrity in clinical research. “For a sponsor, partner or other stakeholder, a ‘Closed’ EIR straight from the FDA says all that needs to be said about how well your quality systems stand up to independent inspection,” added the spokesperson.
Thus GloGen maintains a steadfast commitment to progress, quality conformity and provision of Regulatory compliant Clinical Research Services on global platform.
